NCT05198557View on ClinicalTrials.gov

A Study of MT-0551 in Patients With Systemic Sclerosis

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

July 20, 2022

Primary Completion Date

July 31, 2025

Study Completion Date

August 31, 2026

Conditions
Systemic Sclerosis
Interventions
DRUG

Inebilizumab

Participants will receive IV inebilizumab.

DRUG

Placebo

Participants will receive IV placebo matched to inebilizumab.

Trial Locations (4)

910-1193

University of Fukui Hospital, Yoshida-gun

920-8641

Kanazawa University Hospital, Kanazawa

216-8511

St. Marianna University Hospital, Kawasaki-shi

113-8655

The University of Tokyo Hospital, Bunkyo-ku

Sponsors
All Listed Sponsors
lead

Mitsubishi Tanabe Pharma Corporation

INDUSTRY